Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24786781 | 0.95 | MEN1 (0.31) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL24146397 | 0.93 | MEN1 (0.31) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL24133949 | 0.92 | MEN1 (0.32) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL24786217 | 0.90 | MEN1 (0.31) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL24787734 | 0.90 | MEN1 (0.31) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL24832072 | 0.88 | MEN1 (0.31) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL24147298 | 0.87 | KDM4E (0.35) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL24108091 | 0.87 | — | — | |
| SCHEMBL24108553 | 0.87 | KDM4E (0.31) | MEN1KMT2AALDH1A1KDM4ETSHR | |
| SCHEMBL24108093 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015007729-A1 | PROCESS FOR 1,2,3-TRIYLIDENETRIS(CYANOMETHANYLYLIDENE))TRIS(2,3,5,6-TETRAFLUOROBENZONITRILE)-CYCLOPROPANE | NOVALED GMBH (DE) | 2015-01-22 | — | — | WO | claimed |
| EP-2826768-A1 | Process for manufacturing 1,2,3-triylidenetris(cyanomethanylylidene)tris(2,3,5,6-tetrafluorobenzonitrile)-cyclopropane | Novaled GmbH (DE) | 2015-01-21 | — | — | EP | claimed |
| EP-4635271-A1 | ORGANIC ELECTROLUMINESCENT DEVICE, SEMICONDUCTING MATERIAL, SEMICONDUCTING LAYER, COMPOUND, ELECTRONIC DEVICE AND DISPLAY DEVICE | Novaled GmbH (DE) | 2025-10-22 | — | — | EP | disclosed |
| CN-111480245-B | Light-emitting element, light-emitting device, electronic apparatus, and lighting device | 株式会社半导体能源研究所 | 2025-06-24 | — | — | CN | disclosed |
| CN-120166858-A | Light emitting device | 株式会社半导体能源研究所 | 2025-06-17 | — | — | CN | disclosed |
| CN-120081874-A | Organic compound, light-emitting device, light-emitting apparatus, electronic device, and lighting apparatus | 株式会社半导体能源研究所 | 2025-06-03 | — | — | CN | disclosed |
| CN-120076572-A | Light emitting device | 株式会社半导体能源研究所 | 2025-05-30 | — | — | CN | disclosed |
| CN-119947404-A | Light emitting device | 株式会社半导体能源研究所 | 2025-05-06 | — | — | CN | disclosed |
| CN-119896076-A | Organic electroluminescent device, semiconductor material, semiconductor layer, compound, electronic device, and display device | 诺瓦尔德股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119894227-A | Light emitting element, display device, electronic device, and lighting device | 株式会社半导体能源研究所 | 2025-04-25 | — | — | CN | disclosed |
| CN-119856600-A | Light emitting device and display apparatus | 株式会社半导体能源研究所 | 2025-04-18 | — | — | CN | disclosed |
| US-8057712-B2 | Radialene compounds and their use | NOVALED AG (DE) | 2011-11-15 | — | — | US | disclosed |
| EP-2180029-B1 | Radialene compounds and their use | NOVALED AG (DE) | 2011-07-27 | — | — | EP | disclosed |
| US-7981324-B2 | Oxocarbon-, pseudooxocarbon- and radialene compounds and their use | NOVALED AG (DE) | 2011-07-19 | — | — | US | disclosed |
| US-20100102709-A1 | RADIALENE COMPOUNDS AND THEIR USE | NOVALED AG (DE) | 2010-04-29 | — | — | US | disclosed |
| EP-2180029-A1 | Radialene compounds and their use | Novaled AG (DE) | 2010-04-28 | — | — | EP | disclosed |
| US-20080265216-A1 | Use as doping agent for doping organic semiconductive matrix material, as blocker material, as charge injection layer, as electrode material as well as organic semiconductor, electronic component; 1,3-Bi(dicyanomethylene)indane-2-ylidene-bis(4-oxo-[3,5-di-t-butyl]-2,5-cyclohexadienylidene)cyclopropane | NOVALED AG (DE) | 2008-10-30 | — | — | US | disclosed |
| US-4965394-A | REACTING PENTAFLUOROBENZONITRILE WITH A GRIGNARD REAGENT | ICI AMERICAS INC. | 1990-10-23 | — | — | US | disclosed |
| US-4866185-A | HEAT RESISTANT POLYMERS; CHEMICAL INTERMEDIATES | ICI AMERICAS INC. (US) | 1989-09-12 | — | — | US | disclosed |
| US-4783547-A | Polyfluoroaromatic nitriles | ICI AMERICAS INC. (US) | 1988-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100102709-A1 | RADIALENE COMPOUNDS AND THEIR USE | CHRNB2, CHRNB3, CHRNB4 | MEN1 1668/4885KMT2A 2449/4885MAPT 2673/4885 |
| US-20080265216-A1 | Use as doping agent for doping organic semiconductive matrix material, as blocker material, as charge injection layer, as electrode material as well as organic semiconductor, electronic component; 1,3-Bi(dicyanomethylene)indane-2-ylidene-bis(4-oxo-[3,5-di-t-butyl]-2,5-cyclohexadienylidene)cyclopropane | CHRNB1, GJB2, CHRNB3 | MEN1 3536/4885KMT2A 3588/4885MAPT 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.